「trial」の検索結果

Classical end-to-end empirical analysis workflow in the modern tidyverse + econometrics R ecosystem — dplyr + tidyr + haven + fixest + sandwich + lmtest + clubSandwich + AER + ivreg + did + bacondecomp + HonestDiD + eventstudyr + rdrobust + rddensity + Synth + gsynth + synthdid + MatchIt + WeightIt + cobalt + ebal + grf + DoubleML + mediation + marginaleffects + modelsummary + kableExtra + gt + ggplot2 + ggpubr + cowplot + binsreg. **Defaults to economics empirical-paper style** (AER / QJE / AEJ) — every run produces a publication-ready output set with a multi-column regression table (M1→M6 progressive controls/FE) as the centerpiece, plus Table 1 (descriptives), mechanism / heterogeneity / robustness tables, and event-study + coefficient + trend figures. Covers the full 8-step R pipeline an applied economist runs on every paper — (1) data import & cleaning (read_dta/read_csv, naniar, janitor, validate-merges), (2) variable construction (mutate/across/winsorize/group_by + lag/lead with dplyr), (3) descriptive statistics & Table 1 (gtsummary, modelsummary::datasummary, tableone), (4) classical diagnostic tests (shapiro/jarque.bera.test/bptest/dwtest/bgtest/vif/adf.test/kpss.test/Hausman), (5) baseline modeling (fixest::feols, ivreg, did::att_gt, eventstudyr, sun_ab, did_imputation, synthdid, rdrobust, MatchIt, WeightIt, grf::causal_forest, DoubleML, mediation), (6) robustness battery (modelsummary stack, clubSandwich CRSE, fwildclusterboot, ri2, robomit Oster, bacondecomp, HonestDiD), (7) further analysis (interactions + marginaleffects, mediation::mediate, gsem via lavaan, dose-response splines, grf CATE), (8) publication-ready tables & figures (modelsummary, kableExtra, gt, stargazer, texreg, flextable to LaTeX/Word/HTML; ggplot2 + ggpubr + cowplot + binsreg + iplot for figures). **Also covers two parallel domain modes that share the same 8-step scaffolding** — **Mode A — Epidemiology / public health** (target-trial emulation, IPTW + g-formula + TMLE doubly-robust triplet via `WeightIt` / `gfoRmula` / `tmle` / `ltmle`, Mendelian randomization via `MendelianRandomization` / `TwoSampleMR` / `MRPRESSO`, KM / Cox / AFT / RMST survival via `survival` / `survminer` / `flexsurv`, E-value sensitivity via `EValue`, principal stratification — STROBE / TRIPOD reporting), and **Mode B — ML causal inference** (DML via `DoubleML`, S/T/X/R/DR meta-learners via `causalweight` / `grf`, causal forest via `grf::causal_forest`, BART/BCF via `bartCause` / `bcf`, matrix completion via `MCPanel`, CATE distribution + policy tree via `policytree`, off-policy evaluation, conformal causal via `conformalInference` / `cfcausal`, fairness audit via `fairmodels`, DAG learning via `pcalg` / `bnlearn` / LLM-assisted). Use when the user asks for a complete R empirical analysis, wants a tidyverse-style reproducible R script / Quarto workflow, prefers fixest over reghdfe, needs the R counterpart to StatsPAI / 00.1 / 00.2, or names a specific R step in isolation ("feols with cluster", "MatchIt nearest neighbor", "bacondecomp in R", "gtsummary table 1", "modelsummary to Word"). Mode A triggers on "target trial emulation R", "tmle ltmle", "MendelianRandomization", "TwoSampleMR", "MRPRESSO", "survival cox AFT", "STROBE R", "EValue R", "公共健康 R", "流行病学 R". Mode B triggers on "DoubleML R", "grf causal forest", "policytree", "bartCause bcf", "conformal causal R", "fairmodels", "pcalg NOTEARS", "因果机器学习 R".

日本語の概要は準備中です。原文の説明を表示しています。

Classical end-to-end empirical analysis workflow in the traditional Stata ecosystem — native Stata + reghdfe + ivreg2 + csdid + did_imputation + eventstudyinteract + sdid + rdrobust + rddensity + synth + synth_runner + psmatch2 + teffects + ebalance + coefplot + esttab + asdoc + binscatter. **Defaults to economics empirical-paper style** (AER / QJE / AEJ) — every run produces a publication-ready output set with a multi-column regression table (M1→M6 progressive controls/FE) as the centerpiece, plus Table 1 (descriptives), mechanism / heterogeneity / robustness tables, and event-study + coefficient + trend figures. Covers the full 8-step Stata pipeline an applied economist runs on every paper — (1) data import & cleaning (use/import, destring, misstable, duplicates, merge assert), (2) variable construction (gen/egen/winsor2/xtile/xtset with L./F./D.), (3) descriptive statistics & Table 1 (tabstat/balancetable/asdoc), (4) classical diagnostic tests (sktest/swilk/hettest/imtest/xtserial/xttest3/vif/dfuller/kpss/hausman/estat overid), (5) baseline modeling (reg/xtreg/reghdfe/ivreg2/ivregress/csdid/did_imputation/eventstudyinteract/sdid/rdrobust/synth/psmatch2/teffects/heckman/qreg/ppmlhdfe), (6) robustness battery (bacondecomp/honestdid/rwolf/ritest/wildbootstrap/oster), (7) further analysis (subgroup/triple-diff/interactions/medsem/marginsplot/binscatter by group), (8) publication-ready tables & figures (esttab/outreg2/estout/coefplot/marginsplot/rdplot/twoway combined). **Also covers two parallel domain modes that share the same 8-step scaffolding** — **Mode A — Epidemiology / public health** (target-trial emulation, IPTW + g-formula + TMLE doubly-robust triplet via `teffects ipw` / `teffects ipwra` / `teffects aipw` / `eltmle`, Mendelian randomization via `mrrobust` (IVW / Egger / weighted median) and `mregger` / `mrpresso`, KM / Cox / AFT / RMST survival via `sts` / `stcox` / `streg` / `strmst2`, E-value sensitivity via `evalue` (Linden-Mathur), principal stratification — STROBE / TRIPOD reporting), and **Mode B — ML causal inference** (DML via `ddml` / `pdslasso`, S/T/X/R/DR meta-learners via `crforest` and `ddml interactive`, causal forest via `crforest` / `cforest`, BART/BCF via `bart` / `bartCause`-style externals, CATE distribution + policy tree via `crforest`, off-policy evaluation, conformal causal externals, fairness audit, DAG learning via `pcalg` / external Python callouts). Use when the user asks for a complete Stata empirical analysis, wants a reproducible .do-file pipeline, needs a Stata counterpart to the Python StatsPAI / Full-empirical-analysis-skill, or names a specific Stata step in isolation ("run reghdfe with two-way clustering", "csdid event study", "winsor2 at 1%", "esttab to LaTeX", "coefplot with CI", "ivreg2 weak-IV test", "synth_runner placebos", "teffects psmatch balance check"). Mode A triggers on "target trial emulation Stata", "teffects ipw aipw", "eltmle", "mrrobust", "mregger weighted median", "stcox AFT survival", "strmst2", "evalue Stata", "STROBE Stata", "公共健康 Stata", "流行病学 Stata". Mode B triggers on "ddml Stata", "pdslasso", "crforest causal forest Stata", "policy tree Stata", "因果机器学习 Stata".

日本語の概要は準備中です。原文の説明を表示しています。

Classical end-to-end empirical analysis workflow in the traditional Python econometric stack — pandas + numpy + scipy + statsmodels + linearmodels + pyfixest + rdrobust + econml + causalml + matplotlib/seaborn. **Defaults to economics empirical-paper style** (AER / QJE / AEJ) — every run produces a publication-ready output set with a multi-column regression table (M1→M6 progressive controls/FE) as the centerpiece, plus Table 1 (descriptives), mechanism / heterogeneity / robustness tables, and event-study + coefficient + trend figures. Covers the full 8-step pipeline an applied economist or quantitative social scientist runs on every paper — (1) data cleaning, (2) variable construction & transformation, (3) descriptive statistics & Table 1, (4) statistical diagnostic tests, (5) baseline empirical modeling, (6) robustness battery, (7) further analysis (mechanism, heterogeneity, mediation, moderation), (8) publication-ready tables & figures. **Also covers two parallel domain modes that share the same 8-step scaffolding** — **Mode A — Epidemiology / public health** (target-trial emulation via `zepid` / hand-rolled `pandas`, IPTW + g-formula + TMLE doubly-robust triplet via `zepid` / `econml` / `lifelines`, Mendelian randomization via `pymr` / `mrtool` (or `rpy2` → `MendelianRandomization`/`TwoSampleMR`), KM / AFT / Cox survival via `lifelines`, E-value sensitivity, principal stratification — STROBE / TRIPOD reporting), and **Mode B — ML causal inference** (DML via `econml.dml` / `doubleml`, S/T/X/R/DR meta-learners via `econml.metalearners` / `causalml`, causal forest via `econml.grf` / `causalml`, Dragonnet / TARNet / CEVAE neural causal via `causalml`, BCF via `pymc-bart` / `bcf-py`, matrix completion, CATE distribution + policy tree via `econml.policy` / `policytree-py`, off-policy evaluation, conformal causal via `mapie`, fairness audit via `fairlearn`, DAG learning via `causal-learn` / `cdt` / LLM-assisted). Prescribes which library to reach for at each step, shows the canonical code, and links to deeper `references/` files for variant-specific patterns. Use when the user asks for a **complete empirical analysis** in Python, wants to replicate an applied-economics paper from scratch, needs a reproducible workflow that is NOT opinionated on any single vertical package (contrast with StatsPAI), wants explicit control over every estimator and diagnostic, or asks "how do I write a full empirical pipeline in Python?". Also triggers when the user names a specific classical step in isolation — "winsorize at 1/99%", "run Breusch-Pagan", "build a Table 1 balance table", "do a placebo test", "event study plot", "mediation analysis" — and wants it wired into the broader pipeline. Mode A triggers on "target trial emulation", "IPTW", "TMLE", "Mendelian randomization", "STROBE", "公共健康", "流行病学". Mode B triggers on "DML", "double machine learning", "causal forest", "meta-learner", "Dragonnet", "BCF", "policy tree", "conformal causal", "fairness audit", "因果机器学习".

日本語の概要は準備中です。原文の説明を表示しています。

Use when the user asks to run a full empirical / causal analysis in Python — by default in the style of an applied economics paper (AER / QJE / JPE / ReStud / AEJ) with DID / RD / IV / SCM / DML / matching, written-out estimating equation + identifying assumption, Table 1 / Table 2 / event-study figure / robustness gauntlet — OR in epidemiology / public health style (target-trial emulation, IPTW + g-formula + TMLE triplet, Mendelian randomization, KM/AFT survival, E-value sensitivity, STROBE/TRIPOD reporting) — OR in ML causal inference style (DML, S/T/X/R/DR meta-learners, causal forest, Dragonnet/TARNet/CEVAE, BCF, CATE distribution, policy learning, conformal causal, fairness audit, causal discovery) — OR in distributional / gap-decomposition style (Oaxaca–Blinder `sp.oaxaca`, Kitagawa `sp.kitagawa_decompose`, DiNardo–Fortin–Lemieux `sp.dfl_decompose`, Gelbach `sp.gelbach`, Fairlie `sp.fairlie`, RIF / FFL `sp.rif_decomposition`, all reachable through the `sp.decompose` dispatcher). Also covers exporting multi-column regression tables to Word / Excel / LaTeX (Stata outreg2 / esttab / R modelsummary equivalent) and bundling an entire replication appendix into one .docx / .xlsx / .tex file. Triggers on keywords "StatsPAI", "statspai", "AER empirical analysis", "applied micro pipeline", "Table 1 balance", "event study", "first-stage F", "Oster bound", "honest_did", "spec_curve", "callaway_santanna", "dragonnet", "text as treatment", "outreg2 in Python", "regression table to Word/Excel", "sp.regtable", "sp.collect", "sp.paper_tables", "sp.feols", "summary_col", "modelsummary", "AER style table", "QJE style table", "epidemiology pipeline", "target trial emulation", "g-formula", "IPTW", "TMLE", "Mendelian randomization", "STROBE", "TRIPOD", "公共健康", "流行病学", "DML", "double machine learning", "causal forest", "meta-learner", "CATE", "conformal causal", "policy learning", "因果机器学习", "ML causal", "decomposition", "Oaxaca-Blinder", "Kitagawa", "DiNardo-Fortin-Lemieux", "DFL", "Gelbach", "RIF decomposition", "wage gap decomposition", "sp.decompose", "sp.oaxaca".

日本語の概要は準備中です。原文の説明を表示しています。

When the user wants to optimize their subscription business end-to-end — from trial start through renewal, cancellation, and win-back. Use when the user mentions "subscription lifecycle", "trial conversion", "churn", "cancellation", "win-back", "lapsed subscribers", "dunning", "billing retry", "grace period", "renewal rate", "subscriber LTV", or "resubscribe". For paywall design and pricing strategy, see monetization-strategy. For subscription analytics dashboards, see app-analytics.

日本語の概要は準備中です。原文の説明を表示しています。

Baidu Yijian visual management skill for industrial scenarios. Provides visual recognition capabilities across 20+ industries including retail, energy, mining, ports, chemical, and steel. Use for industrial visual inspection and management.

日本語の概要は準備中です。原文の説明を表示しています。

Analyzes the feasibility of a proposed Meta-analysis topic by searching for existing Meta-analyses and Clinical Trials on PubMed/ClinicalTrials.gov. Use when you need to evaluate if a topic is viable for a new Meta-analysis.

日本語の概要は準備中です。原文の説明を表示しています。

Use when cleaning clinical trial data, preparing data for FDA/EMA submission, standardizing SDTM datasets, handling missing values in clinical studies, detecting outliers in lab results, or converting raw CRF data to CDISC format. Cleans and standardizes clinical trial data fo...

日本語の概要は準備中です。原文の説明を表示しています。

Extracts clinical trial baseline data (study, region, participants, etc.) from article text or PMID. Checks PubMed for metadata; always falls back to LLM extraction for full details.

日本語の概要は準備中です。原文の説明を表示しています。

Performs logistic regression for clinical trial outcomes (binary, ordinal, multinomial) with marginal-vs-conditional estimand reporting per FDA 2023 covariate adjustment guidance, g-computation/standardisation for marginal effects, modified Poisson for RR, Brant test for proportional odds, Firth penalty for separation, and Hauck-Donner detection. Use when modeling binary or ordinal endpoints in confirmatory or exploratory clinical trials.

日本語の概要は準備中です。原文の説明を表示しています。

Reads, validates, and prepares CDISC SDTM and ADaM clinical trial data for analysis. Covers SDTM domain joins (DM, AE, EX, VS, LB, DS), ADaM architecture (ADSL, BDS, OCCDS, ADTTE) with traceability, treatment-emergent AE conventions, baseline derivation, SUPPQUAL/NSV handling, Define-XML 2.1, and Pinnacle 21 / CORE validation. Use when working with clinical trial datasets in CDISC SDTM/ADaM format, preparing analysis-ready data, or validating for regulatory submission.

日本語の概要は準備中です。原文の説明を表示しています。

Performs time-to-event analysis for clinical trials including Cox proportional hazards regression with PH diagnostics, restricted mean survival time (RMST) under non-PH, competing risks via Fine-Gray vs cause-specific Cox, weighted log-rank and MaxCombo for non-proportional hazards, recurrent events (Andersen-Gill, PWP, WLW), and interval-censored data. Use when analyzing time-to-event endpoints (OS, PFS, DOR, TTR, TTNT) in oncology or other clinical trials.

日本語の概要は準備中です。原文の説明を表示しています。

Designs adaptive clinical trials including group-sequential (O'Brien-Fleming, Pocock, Lan-DeMets spending), sample-size re-estimation (blinded Friede-Kieser, unblinded Cui-Hung-Wang, Mehta-Pocock promising zone), seamless Phase 2/3 with treatment-arm selection, population enrichment, and response-adaptive randomisation. Covers FDA 2019 Final Adaptive Designs Guidance, FDA 2022 Master Protocols, and ICH E20 Step 2b/3 draft (June 2025, NOT final). Use when planning interim analyses, sample-size re-estimation, or master/platform-trial designs.

日本語の概要は準備中です。原文の説明を表示しています。

Implements multiplicity control for confirmatory clinical trials using graphical procedures (Bretz-Maurer-Hommel), gatekeeping (parallel, serial, mixed), Hochberg/Hommel/Holm with PRDS, and the closed-testing principle (Marcus-Peritz-Gabriel; Goeman 2021 admissibility). Covers FDA Multiple Endpoints Final Guidance (October 2022), graphical procedures via R gMCP, primary + key-secondary + subgroup hierarchies, and FWER vs FDR distinction. Use when designing the multiplicity strategy for confirmatory trials with multiple primary or key secondary endpoints.

日本語の概要は準備中です。原文の説明を表示しています。

Computes sample size and power for clinical trials including continuous, binary, and time-to-event endpoints; superiority, non-inferiority, and equivalence designs; FDA 2016 non-inferiority margin selection with M1/M2 framework; Schoenfeld 1981 and Lakatos 1988 for survival; Schuirmann TOST and 80-125% bioequivalence; minimum clinically important difference (MCID) vs δ distinction. Use when justifying trial size in protocol or SAP per CONSORT 2025 item 16a.

日本語の概要は準備中です。原文の説明を表示しています。

Prepares statistical reports for clinical trials following CONSORT 2025, SPIRIT 2025, ICH E9(R1) estimands, and FDA 2023 covariate adjustment guidance. Covers Table 1 generation, analysis populations (ITT/FAS/PP/Safety), the 5 ICH E9(R1) intercurrent-event strategies, MMRM under MAR (mmrm), reference-based MI (rbmi J2R/CR/CIR), Permutt tipping-point sensitivity, and Rubin's-rules vs frequentist variance debate. Use when preparing regulatory submissions, defining estimands, or implementing missing-data sensitivity analyses.

日本語の概要は準備中です。原文の説明を表示しています。

Search ClinicalTrials.gov for clinical study information

日本語の概要は準備中です。原文の説明を表示しています。

Expert patterns for racing mechanics, checkpoint tracking, and ghost recording/playback in Godot 4. Use when building racing games, speed-run platformers, or arcade trials.

日本語の概要は準備中です。原文の説明を表示しています。

When the user wants to optimize signup, registration, account creation, or trial activation flows. Also use when the user mentions "signup conversions," "registration friction," "signup form optimization," "free trial signup," "reduce signup dropoff," or "account creation flow." For post-signup onboarding, see onboarding-cro. For lead capture forms (not account creation), see form-cro.

日本語の概要は準備中です。原文の説明を表示しています。

Operational Technology and industrial control system security — Purdue model segmentation, industrial protocol analysis (Modbus, DNP3, S7, EtherNet/IP), PLC/HMI exposure, IEC 62443 alignment, and MITRE ATT&CK for ICS, for authorized and safety-conscious assessments

日本語の概要は準備中です。原文の説明を表示しています。

Query Open Targets GraphQL API for target-disease associations, evidence, drug links, safety. Search targets by gene, diseases by EFO ID; scores from 20+ sources, drug mechanisms, tractability. For ChEMBL use chembl-database-bioactivity; for trials use clinicaltrials-database-search.

日本語の概要は準備中です。原文の説明を表示しています。

Query openFDA REST API for adverse events (FAERS), labeling, product info, recalls, enforcement. Search by drug name, ingredient, MedDRA, or NDC. 1k req/day no key; 120k with free key. For trials use clinicaltrials-database-search; for structures use drugbank-database-access or chembl-database-bioactivity.

日本語の概要は準備中です。原文の説明を表示しています。

This skill should be used when the user needs to perform year-end closing adjustments (決算整理), review financial statements (決算書), compute depreciation, or review their trial balance. Trigger phrases include: "決算", "決算整理", "決算書を作る", "減価償却", "試算表", "残高試算表", "損益計算書", "貸借対照表", "BS", "PL", "期末処理", "棚卸し", "未払計上", "前払処理".

Weekly clinical-trial status diff — the 11-category change report over the stored weekly snapshots (spec 055 FR-B03). Surfaces exactly what changed on the trial registry for your coverage: New / Suspended / Withdrawn / Terminated / Recruiting / Recruitment-Complete / Completed / Ahead / Delayed / Upsized / Downsized, every row carrying previous and new values, with risk flags on Terminated and Downsized and re-timing flags on Ahead and Delayed. The stored-previous-value discipline makes each week's diff reproducible.

日本語の概要は準備中です。原文の説明を表示しています。